138 related articles for article (PubMed ID: 19433805)
1. RNAi screen for rapid therapeutic target identification in leukemia patients.
Tyner JW; Deininger MW; Loriaux MM; Chang BH; Gotlib JR; Willis SG; Erickson H; Kovacsovics T; O'Hare T; Heinrich MC; Druker BJ
Proc Natl Acad Sci U S A; 2009 May; 106(21):8695-700. PubMed ID: 19433805
[TBL] [Abstract][Full Text] [Related]
2. INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.
Liu M; Smith R; Liby T; Chiotti K; López CS; Korkola JE
Breast Cancer Res; 2022 Mar; 24(1):18. PubMed ID: 35248133
[TBL] [Abstract][Full Text] [Related]
3. The multifaceted role of lemur tyrosine kinase 3 in health and disease.
Ditsiou A; Gagliano T; Samuels M; Vella V; Tolias C; Giamas G
Open Biol; 2021 Sep; 11(9):210218. PubMed ID: 34582708
[TBL] [Abstract][Full Text] [Related]
4. Do patients with oral squamous cell carcinoma express receptor tyrosine kinase-like orphan receptor 1? Results of an observational study.
Nema S; Kallianpur S; Kumar A; Nema R; Vishwakarma S; Nema SK
J Oral Maxillofac Pathol; 2021; 25(1):105-109. PubMed ID: 34349419
[TBL] [Abstract][Full Text] [Related]
5.
Tognon CE; Sears RC; Mills GB; Gray JW; Tyner JW
Annu Rev Cancer Biol; 2021 Mar; 5():39-57. PubMed ID: 34222745
[TBL] [Abstract][Full Text] [Related]
6. Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.
K Bhanumathy K; Balagopal A; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Giambra V
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430292
[TBL] [Abstract][Full Text] [Related]
7. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Rummelt C; Gorantla SP; Meggendorfer M; Charlet A; Endres C; Döhner K; Heidel FH; Fischer T; Haferlach T; Duyster J; von Bubnoff N
Leukemia; 2021 Jul; 35(7):2017-2029. PubMed ID: 33149267
[TBL] [Abstract][Full Text] [Related]
8. Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma.
Anderson AN; McClanahan D; Jacobs J; Jeng S; Vigoda M; Blucher AS; Zheng C; Yoo YJ; Hale C; Ouyang X; Clayburgh D; Andersen P; Tyner JW; Bar A; Lucero OM; Leitenberger JJ; McWeeney SK; Kulesz-Martin M
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843430
[TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
Joshi SK; Qian K; Bisson WH; Watanabe-Smith K; Huang A; Bottomly D; Traer E; Tyner JW; McWeeney SK; Davare MA; Druker BJ; Tognon CE
Blood; 2020 Jun; 135(24):2159-2170. PubMed ID: 32315394
[TBL] [Abstract][Full Text] [Related]
10. Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets.
Torres-Ayuso P; Brognard J
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817861
[TBL] [Abstract][Full Text] [Related]
11. RNAi Transfection Optimized in Primary Naïve B Cells for the Targeted Analysis of Human Plasma Cell Differentiation.
Shih T; De S; Barnes BJ
Front Immunol; 2019; 10():1652. PubMed ID: 31396212
[TBL] [Abstract][Full Text] [Related]
12. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
Edwards DK; Watanabe-Smith K; Rofelty A; Damnernsawad A; Laderas T; Lamble A; Lind EF; Kaempf A; Mori M; Rosenberg M; d'Almeida A; Long N; Agarwal A; Sweeney DT; Loriaux M; McWeeney SK; Tyner JW
Blood; 2019 Feb; 133(6):588-599. PubMed ID: 30425048
[TBL] [Abstract][Full Text] [Related]
13. LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
Klug LR; Bannon AE; Javidi-Sharifi N; Town A; Fleming WH; VanSlyke JK; Musil LS; Fletcher JA; Tyner JW; Heinrich MC
Oncogene; 2019 Feb; 38(8):1200-1210. PubMed ID: 30242244
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Jenkins C; Luty SB; Maxson JE; Eide CA; Abel ML; Togiai C; Nemecek ER; Bottomly D; McWeeney SK; Wilmot B; Loriaux M; Chang BH; Tyner JW
Sci Signal; 2018 Jul; 11(539):. PubMed ID: 30018082
[TBL] [Abstract][Full Text] [Related]
15. Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models.
Ouyang X; Barling A; Lesch A; Tyner JW; Choonoo G; Zheng C; Jeng S; West TM; Clayburgh D; Courtneidge SA; McWeeney SK; Kulesz-Martin M
Cancer Biol Ther; 2018; 19(10):921-933. PubMed ID: 29856687
[TBL] [Abstract][Full Text] [Related]
16. Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL.
Chow M; Gao L; MacManiman JD; Bicocca VT; Chang BH; Alumkal JJ; Tyner JW
Oncogene; 2018 Sep; 37(38):5221-5232. PubMed ID: 29849118
[TBL] [Abstract][Full Text] [Related]
17. LMTK3 confers chemo-resistance in breast cancer.
Stebbing J; Shah K; Lit LC; Gagliano T; Ditsiou A; Wang T; Wendler F; Simon T; Szabó KS; O'Hanlon T; Dean M; Roslani AC; Cheah SH; Lee SC; Giamas G
Oncogene; 2018 Jun; 37(23):3113-3130. PubMed ID: 29540829
[TBL] [Abstract][Full Text] [Related]
18. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Merchant AA; Jorapur A; McManus A; Liu R; Krasnoperov V; Chaudhry P; Singh M; Harton L; Agajanian M; Kim M; Triche TJ; Druker BJ; Tyner JW; Gill PS
Blood Adv; 2017 Sep; 1(20):1635-1644. PubMed ID: 29296810
[TBL] [Abstract][Full Text] [Related]
19. Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck.
de Boer DV; Martens-de Kemp SR; Buijze M; Stigter-van Walsum M; Bloemena E; Dietrich R; Leemans CR; van Beusechem VW; Braakhuis BJM; Brakenhoff RH
Oncotarget; 2017 Nov; 8(58):97928-97940. PubMed ID: 29228663
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
